InMed Q3 net loss $3.0M; INM-901 Alzheimer's data positive, BayMedica exit

InMed Pharmaceuticals Inc.

2026-Q3 EPS reported -$1.69

Net loss from continuing ops $2.8M (Q3 FY2026) vs $2.1M prior year; total net loss $3.0M.
R&D spending rose to $1.0M from $0.4M, driven by INM-901 Alzheimer's program costs.
Cash and equivalents decreased to $5.2M as of March 31, 2026 from $10.8M at June 30, 2025.
INM-901 showed anti-neuroinflammatory effects in human 3D brain organoid models of Alzheimer's disease.
Board approved wind down of BayMedica commercial operations, expected completion by June 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.